10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.41), $0.14 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $42.9 million versus the consensus estimate of $29.56 million.

“Due to the efforts and perseverance of the 10x team, we were able to successfully execute across the business and launch a number of breakthrough products in the face of significant challenges during the quarter,” said Serge Saxonov, Co-Founder and CEO of 10x Genomics. “While we may face continued near-term disruption related to the pandemic, recent events have reinforced the importance of mastering biology, and I am as confident as ever in our long-term opportunity.”

For earnings history and earnings-related data on 10x Genomics (TXG) click here.